BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for RW Zink

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of potent and selective retinoic acid receptor gamma (RAR¿) antagonists for the treatment of osteoarthritis pain using structure based drug design.EBI
Eli Lilly
Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptorß agonists.EBI
Eli Lilly
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.EBI
Eli Lilly
Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.EBI
Eli Lilly
Novel 3-Aryl Indoles as Progesterone Receptor Antagonists for Uterine FibroidsEBI
TBA
Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.EBI
Eli Lilly
Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.EBI
Eli Lilly
Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.EBI
Lilly Research Laboratories
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.EBI
Eli Lilly
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).EBI
Lilly Research Laboratories
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.EBI
Eli Lilly